<noscript id="w5p92"><object id="w5p92"></object></noscript>

    1. <nav id="w5p92"><code id="w5p92"></code></nav>

      <nav id="w5p92"></nav>
    2. <dd id="w5p92"></dd>
    3. <nav id="w5p92"><optgroup id="w5p92"></optgroup></nav>

        For the latest updates on our ongoing response to COVID-19, please click here.

        Pipeline

        Last Updated Date: June 22, 2020

        The impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next. We discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases.

        The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

        48

        Clinical Stage Programs1

        16

        NDA/BLA/MAA, P3 and Registrational P2 Trials

        16

        NMEs via In-Licensing, Options, and Product Acquisitions

        4

        Breakthrough Therapy Designations

        1 Including in-licensing, options, and product acquisitions.


        On this page

        Pipeline

        Viral?Diseases

        Emerging Virus

        • Remdesivir

          COVID-19

          Phase 3

        HIV

        • Biktarvy (BIC/FTC/TAF)

          HIV treatment pediatric1

          Phase 3
        • Lenacapavir capsid inhibitor (GS-6207)

          HIV HTE2?

          Phase 2/3 Registrational for HTE²
        • Lenacapavir capsid inhibitor (GS-6207)

          HIV treatment na?ve

          Phase 2
        • Long-acting treatment: 2 bNAbs (GS-5423, GS-2872)

          HIV cure3?

          Phase 2
        • Vesatolimod TLR-7 agonist (GS-9620)

          HIV cure

          Phase 1
        • Elipovimab bNAB (GS-9722)

          HIV cure

          Phase 1
        • Unboosted protease inhibitor (GS-1156)

          HIV treatment

          Phase 1

        HBV

        • Selgantolimod TLR-8 agonist (GS-9688)

          HBV cure

          Phase 2
        • PD-L1 inhibitor (GS-4224)

          HBV cure

          Phase 1

        1 Biktarvy HIV treatment pediatric label extension.

        2 Registrational for heavily treatment-experienced (HTE) patients.

        3 Phase 2 studies are academic collaborations.

        Inflammatory Diseases

        • Filgotinib JAK-1 inhibitor (GS-6034)

          Rheumatoid arthritis

          NDA/BLA/MAA NDA/MAA
        • Filgotinib JAK-1 inhibitor (GS-6034)

          Ulcerative colitis

          Phase 3
        • Filgotinib JAK-1 inhibitor (GS-6034)

          Crohn's disease

          Phase 3
        • Filgotinib JAK-1 inhibitor (GS-6034)

          Psoriatic arthritis

          Phase 3
        • Filgotinib JAK-1 inhibitor (GS-6034)

          Ankylosing spondylitis

          Phase 2
        • Filgotinib JAK-1 inhibitor (GS-6034)

          Uveitis

          Phase 2
        • TPL2 inhibitor (GS-4875)

          Ulcerative colitis

          Phase 2
        • GLPG-19721?

          Osteoarthritis

          Phase 2
        • GLPG-05551

          Inflammatory diseases

          Phase 1
        • GLPG-33121

          Inflammatory diseases

          Phase 1
        • GLPG-39701

          Inflammatory diseases

          Phase 1
        • GLPG-36671

          Inflammatory diseases

          Phase 1
        • GLPG-31211

          Inflammatory diseases

          Phase 1

        Fibrotic Diseases

        • Cilofexor FXR agonist (GS-9674)

          PSC

          Phase 3
        • GLPG-16902

          Idiopathic pulmonary fibrosis

          Phase 3
        • Selonsertib ASK1 inhibitor (GS-4997)

          DKD

          Phase 2
        • Cilofexor, firsocostat, selonsertib combination3

          NASH

          Phase 2
        • GLPG-16902

          Systemic sclerosis

          Phase 2
        • GLPG-12051

          Idiopathic pulmonary fibrosis

          Phase 2

        1 Optionable partner program.

        2 Optioned partner program.

        3 Cilofexor FXR agonist, firsocostat ACC inh., selonsertib ASK1 inh. combination.

        Oncology

        Cell Therapy

        • KTE-X19

          r/r MCL

          NDA/BLA/MAA BLA/MAA
        • Axi-cel

          2L DLBCL

          Phase 3
        • Axi-cel

          Indolent NHL

          Phase 2 Pivotal
        • Axi-cel

          1L DLBCL

          Phase 2
        • Axi-cel

          3L DLBCL (+rituximab or lenalidomide)

          Phase 2
        • KTE-X19

          Adult ALL

          Phase 2 Pivotal
        • KTE-X19

          Pediatric ALL

          Phase 2 Pivotal
        • KTE-X19

          CLL

          Phase 1
        • Axi-cel

          3L DLBCL (+utomilumab)

          Phase 1
        • KITE-718 (MAGE-A3/A6)

          Solid tumor

          Phase 1
        • KITE-439 (HPV-16 E7)

          Solid tumor

          Phase 1

        Non-Cell Therapy

        • Anti-CD47 (magrolimab)

          MDS

          Phase 3
        • Anti-CD47 (magrolimab)

          AML

          Phase 2
        • Anti-CD47 (magrolimab)

          NHL

          Phase 2
        • Anti-CD47 (magrolimab)

          Exploring solid tumor options

          Phase 1/2
        • Oral PD-L1 inhibitor (GS-4224)

          Solid tumor

          Phase 1
        • Anti-CD73/TGF? TRAP (GS-1423)1

          Solid tumor

          Phase 1
        • Bi-specific mAb (AGEN1223)2,3,4

          Multiple

          Phase 1
        • Anti-CD137 mAb (AGEN2373)3,4

          Multiple

          Phase 1

        1 TME conditioning anti-CD73/TGFß TRAP bifunctional fusion protein (GS-1423).

        2 Bi-specific mAb targeting immunosuppressive regulatory T cells (AGEN1223).

        3 Exclusive option to license right from Agenus upon proof of concept data.

        4 Optionable partner program.

        ALL - Acute lymphocytic leukemia.
        CLL - Chronic lymphocytic leukemia.
        DLBCL - Diffuse large B-cell lymphoma.
        iNHL - Indolent non-Hodgkin lymphoma.
        MCL - Mantle cell lymphoma.
        r/r - relapsed refractory.

        Some of the content on this page is not intended for users outside the US.

        www.黄色网站.com